Paper Details

  1. Home
  2. Paper Details

Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Author: JachimowiczEdward, RainvilleNicole, WojchowskiDon M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy), and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly, and may affect cancer progression. Potentially high merit therefore exists for defining new targets for anti-anemia agents within erythropoietin (EPO) and EPO receptor (EPOR) regulatory circuits.
Paper Details　
Original Abstract of the Article :
Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy), and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly, and may affect cancer progression. Poten...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26419263

データ提供：米国国立医学図書館（NLM）

Targeting EPO and EPO Receptor Pathways in Anemia

Anemia, a condition characterized by a deficiency of red blood cells, is a prevalent health issue. While recombinant human erythropoietin (rhEPO) has been a mainstay treatment, it is not without its drawbacks, including potential side effects and high cost. This study seeks to identify novel targets for anti-anemia agents by exploring the intricate regulatory circuits involving erythropoietin (EPO) and its receptor (EPOR).

Beyond the Basics

This research points to promising new avenues for developing anti-anemia therapies. The study's focus on understanding the EPO and EPOR pathways offers hope for developing more effective and safer treatments for anemia.

Implications for Anemia Management

This study provides valuable insights for patients with anemia and their healthcare providers. The focus on new targets for anti-anemia agents could lead to more effective and personalized treatment options.

Dr.Camel's Conclusion

Just as a camel can traverse vast deserts seeking water, researchers are diligently seeking new approaches to combat anemia. This study illuminates the complex world of EPO and EPOR signaling, providing a roadmap for developing more effective and personalized treatments for this common health challenge.

Date :
  1. Date Completed 2016-09-29
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26419263

DOI: Digital Object Identifier

NIHMS773849

Related Literature

Article Analysis
・Side Effects of zidovudine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.